A porcine xenograft‐derived bone scaffold is a biocompatible bone graft substitute: An assessment of cytocompatibility and the alpha‐Gal epitope

• DOI: 10.1111/xen.12534
• Publication Date: 2019-07-25T07:45:39Z
• Authors: Daniel N. Bracey; Thorsten M. Seyler; Alexander H. Jinnah; Thomas L. Smith; David A. Ornelles; Rajendar Deora; Griffith D. Parks; Mark E. Van Dyke; Patrick W. Whitlock
• Keywords: Decellularization

Abstract Background Xenografts are an attractive alternative to traditional bone grafts because of the large supply from donors with predictable morphology and biology as well minimal risk human disease transmission. Clinical series involving xenograft transplantation, most commonly bovine sources, have reported poor results frequent graft rejection failure integrate host tissue. Failures been attributed residual alpha‐Gal epitope in which humans produce natural antibody against. To authors' knowledge, there is currently no xenograft‐derived substitute that has adopted by orthopedic surgeons for routine clinical use. Methods In current study, a scaffold intended serve was derived porcine cancellous using tissue decellularization chemical oxidation protocol. vitro cytocompatibility, pathogen clearance, quantification tests were used assess safety Results studies showed free processing chemicals biocompatible mouse cell lines. When bacterial viral pathogens purposefully added donor tissue, successfully removed these comply sterility assurance levels established allograft providers. Critically, 98.5% after shown ELISA inhibition assay immunohistochemical staining. Conclusions The investigation supports biologic scaffolds protocol meets standards. majority highly immunogenic carbohydrate findings support further vivo application.